📜 What This Document Is

This is a DEF 14A (Definitive Proxy Statement) for ProMIS Neurosciences. Think of it as a detailed invitation and instruction manual for the company's 2026 Annual Shareholder Meeting. It tells shareholders what's being voted on, who the candidates are, and how the company is run.

Why it matters: This is your chance as a shareholder to have a say in major company decisions, from electing the board to approving key plans.
The Meeting: It's virtual on May 20, 2026, at 10:30 a.m. ET. Shareholders must register in advance to attend and vote.
Key Date: Only shareholders who owned stock by March 23, 2026 (Record Date) can vote. There were 8,967,693 shares outstanding.

🧠 What ProMIS Neurosciences Does

In simple terms, ProMIS is a clinical-stage biotechnology company focused on developing precision medicines for neurodegenerative diseases like Alzheimer's and ALS.

👉 Their core technology uses computational protein design to create "precision conformational" antibodies. These antibodies are engineered to specifically target the toxic, misfolded proteins believed to cause brain diseases, while avoiding the normal, healthy proteins.

Lead Candidate: Their most advanced drug is PMN310, targeted for early Alzheimer's disease. This is their highest-priority asset.
Industry: They operate in the high-risk, high-reward world of biotech R&D. Success depends on clinical trial results and regulatory approvals.

🗳️ The Three Things You're Voting On

The meeting has three main proposals. The Board recommends voting FOR all of them.

Elect 7 Directors 👥: Choose the people who will oversee the company. There's a notable change: Patrick Kirwin is not being re-nominated after a board review. New nominee Slanix Alex (from major shareholder Ally Bridge Group) is proposed.
- Why it matters: The board is reshaping itself. Adding a director from a large investor signals a focus on capital markets expertise as the company advances PMN310.
Ratify the Auditor ✅: Approve Baker Tilly US, LLP as the independent accounting firm for 2026.
- Why it matters: This is a routine but essential check on the company's financial reporting.
Amend the Stock Option Plan 📈: Increase the number of shares available under the 2025 Stock Option and Incentive Plan by 900,000 shares.
- Why it matters: This allows the company to keep attracting and retaining top talent with equity. However, it also dilutes existing shareholders slightly.

💰 The Company's Financial Snapshot (2025)

ProMIS is pre-revenue, which is common for a clinical-stage biotech. Their financial story is about spending cash to fund research.

Net Loss: $28.0 million for the year ended Dec 31, 2025. This is their "burn rate."
Cash Position: $81.2 million in cash and short-term investments as of Dec 31, 2025.
Runway: Management estimates this cash is sufficient to fund operations into 2027.
- Why it matters: The cash runway is critical. They have time to advance PMN310, but will eventually need more funding (through partnerships, stock offerings, etc.), which could impact shareholders.

👥 Meet the Leadership & Board

The people in charge and those nominated to oversee them.

CEO: Neil Warma (since Jan 2024). He's a seasoned biotech executive.
Board Nominees: The slate includes CEO Neil Warma, CSO Neil Cashman, Chairman Eugene Williams, and independent directors like Maggie Shafmaster and new nominee Slanix Alex.
Notable Exit: Director Patrick Kirwin is not standing for re-election after the board's periodic review of its composition.
Executive Pay: The CEO's total compensation for 2025 was $864,167, mostly in salary and bonuses tied to clinical goals. Other executives received between $400k-$600k.

📊 Major Shareholders

A handful of large investment funds own significant chunks of the company.

Top Owners: Funds affiliated with Janus Henderson (14.99%), Ally Bridge Group (9.99%), Deep Track (9.99%), and Wellington (9.99%) are the largest shareholders.
Insiders & Directors: As a group, directors and executive officers own about 1.50% of the company.
- Why it matters: These big funds have a strong voice. The election of Ally Bridge's Dr. Alex to the board formalizes that influential relationship.

⚖️ Governance & Legal Checks

The proxy details the company's governance rules and confirms there are no major legal red flags for directors.

Virtual Meeting: The meeting is fully online. Procedures are outlined for attending, voting, and asking questions.
Board Assessment: The board regularly reviews its own performance and composition, which led to the decision to change one director seat.
No Major Issues: The filing confirms no directors have been involved in bankruptcies, cease-trade orders, or significant securities law penalties.
- Why it matters: This provides reassurance about the basic integrity and oversight structure of the company.

🔮 What's Next & The Big Picture

The annual meeting is about governance, but the real story is the company's next clinical steps.

Strategic Focus: All eyes are on the PMN310 clinical trial. Positive data is the single most important catalyst for the company's future value.
Financial Needs: The $81.2 million cash provides a runway into 2027, but future funding will be needed, likely from partners or the market.
Board Signals: Adding a director from a major fund (Ally Bridge) suggests a focus on strategic partnerships and financial markets as the lead drug advances.

👍 Strengths: Focused pipeline, experienced management, decent cash runway, supportive major shareholders. ⚠️ Risks: Clinical trial failure is the core risk. Future financing could dilute shareholders. Competition in Alzheimer's is intense.

🧠 The Analogy

Think of ProMIS as a specialized racing team (the company) with a promising but unproven engine (PMN310) built for a very tough race (Alzheimer's). The crew chiefs and owners (the Board) are changing a few key positions to bring in a new engineer (Slanix Alex) from a major sponsor (Ally Bridge). They've refueled the car with $81 million, but the race is long, and they'll need another pit stop (more funding) before the finish line.

🧩 Final Takeaway

This meeting is about updating the governance playbook for a high-stakes clinical race. The key moves are shuffling the board to include a major investor and stocking up on equity currency to attract talent. While these are important administrative steps, the company's fate truly rests on the upcoming clinical trial results for PMN310.

ProMIS Neurosciences Inc. — DEF 14A Filing